Top
Main

All outcomes

Feedback
Home
Top   Main   All Outcomes
Loading...
Home   COVID-19 treatment studies for Melatonin  COVID-19 treatment studies for Melatonin  C19 studies: Melatonin  Melatonin   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Povidone-Iod.. (meta)
Conv. Plasma (meta) Probiotics (meta)
Curcumin (meta) Proxalutamide (meta)
Ensovibep (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychlor.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
N-acetylcys..
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc
Supplementary Data — Melatonin for COVID-19: real-time meta analysis of 12 studies
Covid Analysis, January 14, 2022, DRAFT
https://c19melatonin.com/meta.html
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lissoni 91% 0.09 [0.01-1.57] hosp. 0/30 5/30 CT​1 Improvement, RR [CI] Treatment Control Alizadeh (SB RCT) 73% 0.27 [0.07-1.05] no recov. 2/14 9/17 Ramlall 87% 0.13 [0.08-0.22] death 196 (n) 752 (n) Darban (RCT) 33% 0.67 [0.14-3.17] progression 2/10 3/10 CT​1 Darban (RCT) 6% 0.94 [0.84-1.06] ICU 10 (n) 10 (n) CT​1 Hosseini 48% 0.52 [0.36-0.77] recov. time 20 (n) 20 (n) Farnoosh (DB RCT) 81% 0.19 [0.01-3.65] ICU 0/24 2/20 Farnoosh (DB RCT) 49% 0.51 [0.32-0.81] recov. time 24 (n) 20 (n) Farnoosh (DB RCT) 44% 0.56 [0.10-3.00] no disch. 2/24 3/20 Farnoosh (DB RCT) 43% 0.57 [0.35-0.92] no disch. 24 (n) 20 (n) Sánchez-González 54% 0.46 [0.28-0.71] death 24/224 53/224 Mousavi (RCT) 67% 0.33 [0.04-3.09] death 1/48 3/48 Mousavi (RCT) 40% 0.60 [0.24-1.52] ICU 6/48 10/48 Hasan (RCT) 93% 0.07 [0.01-0.53] death 1/82 13/76 Bologna 50% 0.50 [0.13-1.86] death 3/40 6/40 Bologna 50% 0.50 [0.13-1.86] ICU 3/40 6/40 Bologna 9% 0.91 [0.83-1.00] hosp. time 40 (n) 40 (n) Bologna 39% 0.61 [0.53-0.71] s-i time 40 (n) 40 (n) Bologna 58% 0.42 [0.33-0.52] NIV time 40 (n) 40 (n) Bologna 8% 0.92 [0.78-1.09] HFO time 40 (n) 40 (n) Bologna 18% 0.82 [0.74-0.90] sleep 40 (n) 40 (n) Bologna 33% 0.67 [0.54-0.82] delirium 40 (n) 40 (n) Jehi 58% 0.42 [0.26-0.68] cases 16/529 802/11,143 Jehi 100% 0.00 [0.00-0.05] cases 0/18 290/2,005 Zhou (PSM) 21% 0.79 [0.65-0.94] cases melatonin COVID-19 outcomes c19melatonin.com Jan 14, 2022 1 CT: study uses combined treatment Favors melatonin Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. WCH and FLCCC provide treatment protocols.
  or use drag and drop   
Submit